ESPE2015 Poster Category 3 Turner (14 abstracts)
aPediatric Clinic, Department of Life and Reproduction Sciences, University of Verona, Verona, Italy; bClinical Chemistry Section, Department of Life and Reproductive Sciences, University of Verona, Verona, Italy
Background: Different studies have underlined the role of anti-Müllerian hormone (AMH) and inhibin B as markers of the ovarian function in paediatric and adolescent patients with Turner syndrome (TS).
Objective and hypotheses: Our study aims to verify the role of AMH in a cohort of patients affected by TS.
Method: We analysed 23 TS patients, aged 234 years, describing their auxological parameters and the pubertal development, and evaluating their hormonal (AMH, FSH, LH, estradiol, and inhibin B) levels.
Results: Twenty-one out of 23 (91.3%) were treated with GH. AMH resulted measurable only in two patients of 23 (8.7%), whereas inhibin B was measurable in 13 of 23 (56.5%) patients. Our results were highly heterogeneous. In particular, there are predictive factors neither for the response to GH treatment nor by the puberty. In fact, a good response of GH treatment both as final height and in relation to ΔTH (final height- mid-parental height) was independent from karyotype, from hormonal levels and from spontaneous puberty development. In addition, a karyotype 45X0 was not predictive of worst height gain or of not spontaneous pubertal development.
Conclusion: There is not a predictive factor that allows to know in advance the evolution of puberty in patients with TS. A single determination of AMH is not informative; only repeated evaluations of this ovarian marker in childhood and adolescence may be useful to predict a spontaneous beginning of puberty and to suggest a possible fertility.